Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049374 | 0.87 | L3MBTL1 (0.48) | L3MBTL1CYP2D6GSK3BPDE2ARAB9A | |
| SCHEMBL19002801 | 0.85 | MMP1 (0.45) | L3MBTL1CYP2D6GSK3BPDE2AKDM4E | |
| SCHEMBL18997547 | 0.84 | DRD3 (0.58) | DRD3USP30DRD2CHRM2HTR1A | |
| SCHEMBL19002671 | 0.84 | DRD3 (0.46) | L3MBTL1CYP2D6GSK3BPDE2ARAB9A | |
| SCHEMBL18997540 | 0.83 | RIPK1 (0.48) | L3MBTL1PDE2AMAPK1DRD3LMNA | |
| SCHEMBL18997543 | 0.83 | RIPK1 (0.52) | PDE2ARAB9ADRD3USP30NPC1 | |
| SCHEMBL14008975 | 0.82 | USP30 (0.51) | SMN1; SMN2DRD3LMNAUSP30 | |
| SCHEMBL21438214 | 0.82 | CYP2D6 (0.44) | L3MBTL1CYP2D6GSK3BPDE2ARAB9A | |
| SCHEMBL14008939 | 0.82 | DRD2 (0.53) | RAB9AALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL18997534 | 0.81 | DRD3 (0.44) | L3MBTL1DRD3USP30DRD2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC | 2019-01-24 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | L3MBTL1 4204/4885CYP2D6 4551/4885GSK3B 294/4885 |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | L3MBTL1 4409/4885CYP2D6 3985/4885GSK3B 357/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | L3MBTL1 4204/4885CYP2D6 4551/4885GSK3B 294/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | L3MBTL1 4204/4885CYP2D6 4551/4885GSK3B 294/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | L3MBTL1 4204/4885CYP2D6 4551/4885GSK3B 294/4885 |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | L3MBTL1 1677/4885CYP2D6 4785/4885GSK3B 3860/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | L3MBTL1 4204/4885CYP2D6 4551/4885GSK3B 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.